Reuters - A new way of conducting clinical trials could allow Novartis AG to cut the time needed to develop some drugs by a year, the Swiss drug maker’s designated development head said on Wednesday.
Reuters - A new way of conducting clinical trials could allow Novartis AG to cut the time needed to develop some drugs by a year, the Swiss drug maker’s designated development head said on Wednesday.
